Designing equitable antiretroviral allocation strategies in resource-constrained countries.
BACKGROUND
Recently, a global commitment has been made to expand access to antiretrovirals (ARVs) in the developing world. However, in many resource-constrained countries the number of individuals infected with HIV in need of treatment will far exceed the supply of ARVs, and only a limited number of health-care facilities (HCFs) will be available for ARV distribution. Deciding how to allocate the limited supply of ARVs among HCFs will be extremely difficult. Resource allocation decisions can be made on the basis of many epidemiological, ethical, or preferential treatment priority criteria.


RESULTS
Here we use operations research techniques, and we show how to determine the optimal strategy for allocating ARVs among HCFs in order to satisfy the equitable criterion that each individual infected with HIV has an equal chance of receiving ARVs. We present a novel spatial mathematical model that includes heterogeneity in treatment accessibility. We show how to use our theoretical framework, in conjunction with an equity objective function, to determine an optimal equitable allocation strategy (OEAS) for ARVs in resource-constrained regions. Our equity objective function enables us to apply the egalitarian principle of equity with respect to access to health care. We use data from the detailed ARV rollout plan designed by the government of South Africa to determine an OEAS for the province of KwaZulu-Natal. We determine the OEAS for KwaZulu-Natal, and we then compare this OEAS with two other ARV allocation strategies: (i) allocating ARVs only to Durban (the largest urban city in KwaZulu-Natal province) and (ii) allocating ARVs equally to all available HCFs. In addition, we compare the OEAS to the current allocation plan of the South African government (which is based upon allocating ARVs to 17 HCFs). We show that our OEAS significantly improves equity in treatment accessibility in comparison with these three ARV allocation strategies. We also quantify how the size of the catchment region surrounding each HCF, and the number of HCFs utilized for ARV distribution, alters the OEAS and the probability of achieving equity in treatment accessibility. We calculate that in order to achieve the greatest degree of treatment equity for individuals with HIV in KwaZulu-Natal, the ARVs should be allocated to 54 HCFs and each HCF should serve a catchment region of 40 to 60 km.


CONCLUSIONS
Our OEAS would substantially improve equality in treatment accessibility in comparison with other allocation strategies. Furthermore, our OEAS is extremely different from the currently planned strategy. We suggest that our novel methodology be used to design optimal ARV allocation strategies for resource-constrained countries.
Wilson
David P
DP
Department of Biomathematics, AIDS Institute, School of Medicine, University of California, Los Angeles, California, USA.
Blower
Sally M
SM
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D044966:Anti-Retroviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003657:Decision Making; D003906:Developing Countries; D004992:Ethics, Medical; D006291:Health Policy; D006801:Humans; D040841:Resource Allocation
D044966:Anti-Retroviral Agents
Math Biosci. 1999 Feb;155(2):77-109
10067074
Proc R Soc Lond B Biol Sci. 1986 Nov 22;229(1255):111-50
2880348
Health Econ. 2003 Sep;12(9):755-70
12950094
Int J Health Plann Manage. 1999 Apr-Jun;14(2):81-105
10538937
Bull Math Biol. 2001 Jul;63(4):603-24
11497160
Science. 2000 Jan 28;287(5453):650-4
10649998
Int J Health Geogr. 2004 Jul 7;3(1):13
15239839
AIDS. 2005 Jan 3;19(1):1-14
15627028
Nat Med. 2001 Sep;7(9):1016-20
11533704
Am Nat. 2004 Aug;164(2):267-81
15278849
J Infect Dis. 2004 Nov 1;190(9):1610-7
15478066
JAMA. 2002 Oct 2;288(13):1652-3
12350202
Int J Health Geogr. 2004 Feb 26;3(1):3
14987337
Math Biosci. 2003 Jan;181(1):17-54
12421551
Nurs Clin North Am. 1993 Mar;28(1):123-30
8451203
Bioethics. 2003 Oct;17(5-6):387-98
14870761
Trop Med Int Health. 2003 Oct;8(10):917-26
14516303
EMBO Rep. 2003 Jun;4 Spec No:S20-3
12789400
Nature. 2001 Dec 13;414(6865):716-23
11742391